Artificial Intelligence and Cancer Staging in Upper Gastrointestinal Malignancies

Launched by SEBAHATTIN CELIK MD · Dec 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence (AI) can help doctors better stage (or classify) esophageal and stomach cancers. Staging is crucial because it helps determine how serious the cancer is, which directly impacts treatment options and survival rates. In this trial, researchers aim to see if AI can improve the accuracy of cancer staging by analyzing tomography images—specialized scans that show detailed pictures of the body. They also want to look at how well patients do after treatment, including any complications they might face.

To participate in this study, you must be over 18 and have been diagnosed with esophageal cancer, either adenocarcinoma or squamous cell carcinoma. You should also have tomography images taken before or after chemotherapy and be willing to give your consent to join the study. Participants can expect to undergo imaging tests and receive monitoring throughout the process. Overall, this research could lead to better treatment planning and outcomes for people with these types of cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Being diagnosed with esophageal cancer (adenocarcinoma or squamous cancer)
• • 2. Being over 18 years old
• • 3. Having a tomography image before or after chemotherapy.
• • 4. Giving informed consent to participate in the study.
• • 5. Having final pathological staging after surgery.
• Exclusion Criteria:
• • 1. Previous thoracic surgery.
• • 2. Having a recurrent tumor
• • 3. Inability to perform clinical staging due to technical reasons
• • 4. Drawings cannot be made due to poor tomography quality.